Abcellera Biologics is trading 10.7% up at $14.05, though the cause of the intraday rise remains unclear. - No clear new company-specific announcement on September 28 explains the move. - The latest company release found was the September 16 announcement of an upcoming ABCL635 Phase 2 data presentation. - Broader markets are lower amid rising oil prices, Treasury yields, and renewed U.S.–Iran tensions; the gain appears stock-specific.